Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

antibody-drug conjugates (ADCs)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (18) ADC Cytotoxin (60) ADC Linker (702) Antibody-Drug Conjugates (ADCs) (59) Drug Intermediate (14) Drug Metabolite (1) Drug-Linker Conjugates for ADC (48) E3 Ligase Ligand-Linker Conjugates (1) Target Protein Ligand-Linker Conjugates (1) Amino Acid Derivatives (1) Antibiotic (1) Antifolate (1) Apoptosis (15) Bacterial (6) Biochemical Assay Reagents (2) c-Met/HGFR (2) CCR (6) CD19 (1) CD22 (4) CD276/B7-H3 (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (9) DNA/RNA Synthesis (3) EGFR (14) FGFR (1) Glucocorticoid Receptor (5) Guanylate Cyclase (1) Integrin (1) Isotope-Labeled Compounds (4) Kinesin (1) MDM-2/p53 (1) Mesothelin (1) Microtubule/Tubulin (51) Mitochondrial Metabolism (1) Mucin (1) NAMPT (2) Nectin-4 (1) Notch (2) PD-1/PD-L1 (2) Phosphodiesterase (PDE) (1) PROTAC Linkers (205) Sodium Channel (4) STING (3) TAM Receptor (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) Topoisomerase (23) Transmembrane Glycoprotein (1) TROP2 (5)
By Research Areas:	Cancer (904) Cardiovascular Disease (1) Infection (8) Inflammation/Immunology (40) Metabolic Disease (1)
Click Chemistry:	ADC Synthesis (229) TCO (14) DBCO (53) PROTAC Synthesis (53) Azide (80) BCN (21) Tetrazine (31) Alkynes (43)

936

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

235

Click Chemistry

Targets Recommended: Antibody-Drug Conjugates (ADCs) ADC Linker ADC Antibody Drug-Linker Conjugates for ADC Peptide-Drug Conjugates (PDCs) Radionuclide-Drug Conjugates (RDCs) Drug Intermediate Drug Isomer Drug Derivative Drug Metabolite PROTAC-Linker Conjugates for PAC Target Protein Ligand-Linker Conjugates ADC Cytotoxin E3 Ligase Ligand-Linker Conjugates

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W457085

PD-1/PD-L1-IN-29 intermediate-2	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 intermediate-2 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-W047496

AN-12-H5 intermediate-2	Drug Intermediate	Infection
AN-12-H5 intermediate-2 is an intermediate of the viral inhibitor AN-12-H5 (HY-120900) and can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-W451820

AN-12-H5 intermediate-3	Drug Intermediate	Infection
AN-12-H5 intermediate-3 is an intermediate of the viral inhibitor AN-12-H5 (HY-120900) and can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-148245

OH-Glu-Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
OH-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-22055B

AN-12-H5 intermediate-1 (2S,4S)-1-tert-butyl 2-methyl-4-hydroxypiperidine-1,2-dicarboxylate	Drug Intermediate	Infection
AN-12-H5 intermediate-1 ((2S,4S)-1-tert-butyl 2-methyl-4-hydroxypiperidine-1,2-dicarboxylate) is an intermediate of the viral inhibitor AN-12-H5 (HY-120900) and can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-42146

BMPS	ADC Linker	Cancer
BMPS is a nonclaevable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-139441

DM21	Drug-Linker Conjugates for ADC	Cancer
DM21 is a conjugate of a cleavable ADC agent and a linker (ADC linker) used in the synthesis of antibody-drug conjugates (ADCs) .

HY-48934

PD-1/PD-L1-IN-29 intermediate-1	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 intermediate-1 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-162941

SGD-9501-TFA	ADC Linker	Cancer
GD-9501-TFA is an auristatin S-based ADC linker with effective off-target toxicity characteristics, which can be used for the preparation of antibody-drug conjugates (ADCs) .

HY-W598456

Brigimadlin intermediate-1	Drug Intermediate	Cancer
Brigimadlin intermediate-1 is an intermediate of the E3 ubiquitin protein ligase MDM-2 inhibitor Brigimadlin (HY-152859) and can be used to synthesize Antibody-Drug Conjugates (ADCs) .

HY-129369

SPDMB	ADC Linker	Cancer
SPDMB is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs) .

HY-129366

PDB-Pfp	ADC Linker	Cancer
PDB-Pfp is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-12448

SPDB	ADC Linker	Cancer
SPDB is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs) .

HY-129368

SPDMV	ADC Linker	Cancer
SPDMV is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs) .

HY-129373

SPDMV-sulfo	ADC Linker	Cancer
SPDMV-sulfo is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs).

HY-126667

SC-Val-Cit-PAB	ADC Linker	Cancer
SC-Val-Cit-PAB is a cleavable ADC linker for antibody-drug conjugates (ADCs).

HY-137774

Clezutoclax	Drug-Linker Conjugates for ADC	Cancer
Clezutoclax is a agent-linker conjugate for ADC . Clezutoclax can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-126531

DMAC-PDB	ADC Linker	Cancer
DMAC-PDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-150043A

MDTF	ADC Linker	Cancer
MDTF is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-130111

DMAC-SPP	ADC Linker	Cancer
DMAC-SPP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-140014

Val-Cit	ADC Linker	Cancer
Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-160157

IM-2	Drug-Linker Conjugates for ADC	Cancer
IM-2 is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-101151

sulfo-SPDB	ADC Linker	Cancer
sulfo-SPDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-128970

Mp-polymer ester	ADC Linker	Cancer
Mp-polymer ester is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133540

Maleimide-DOTA 2 Publications Verification Maleimido-mono-amide-DOTA	ADC Linker	Inflammation/Immunology Cancer
Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-126349

DTSSP Crosslinker	ADC Linker	Cancer
DTSSP Crosslinker is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-140098

Boc-Cystamine	ADC Linker	Cancer
Boc-Cystamine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-118759

DSP Crosslinker 1 Publications Verification	ADC Linker	Inflammation/Immunology
DSP Crosslinker is a cleavable ADC linker, used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133550

DMAC-SPDB	ADC Linker	Cancer
DMAC-SPDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-126405

SMPT	ADC Linker	Cancer
SMPT is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133542

Dimethylamine-SPDB	ADC Linker	Cancer
Dimethylamine-SPDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-129370

SPDB-sulfo	ADC Linker	Cancer
SPDB-sulfo is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs) .

HY-W071006

PPC-NHS ester 2,5-Dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate	ADC Linker	Cancer
PPC-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133543

SPDP-sulfo	ADC Linker	Cancer
SPDP-sulfo is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-114697

DSG Crosslinker 1 Publications Verification Disuccinimidyl glutarate	ADC Linker	Inflammation/Immunology
DSG Crosslinker is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-129365

SNPB	ADC Linker	Cancer
SNPB is a cleavable linker that is used for making antibody-drug conjugate *(ADC)*.

HY-126495A

Sulfo-LC-SPDP sodium	ADC Linker	Cancer
Sulfo-LC-SPDP sodium is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-138327

1,6-Bis(mesyloxy)hexane	ADC Linker	Cancer
16-Bismesyloxyhexane is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-140987

5-Maleimidovaleric acid	ADC Linker	Cancer
5-Maleimidovaleric acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-130110

Sulfo-DMAC-SPP	ADC Linker	Cancer
Sulfo-DMAC-SPP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-41919

Mal-L-PA-NH-Boc mDPR(boc); (S)-MALEOYL-DPR(BOC)-OH·DCHA	ADC Linker	Cancer
Mal-L-PA-NH-Boc is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-44246

MC-Gly-Gly-Phe-Gly 1 Publications Verification	ADC Linker	Cancer
MC-Gly-Gly-Phe-Gly is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-141158

N-(Iodoacetamido)-Doxorubicin	ADC Linker	Cancer
N-(Iodoacetamido)-Doxorubicin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-126364

Mc-Val-Ala-PAB	ADC Linker	Cancer
Mc- Val- Ala- PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-160790

β-Glu-PNP	ADC Linker	Cancer
β-Glu-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-164732

Fmoc-Lys(DOTA)-OH	ADC Linker	Cancer
Fmoc-Lys(DOTA)-OH is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-140096

Aminoethyl-SS-propionic acid	ADC Linker	Cancer
Aminoethyl-SS-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-126496

PEG4-SPDP	ADC Linker	Cancer
PEG4-SPDP is a cleavable ADC linker used for the antibody-drug conjugates (ADCs).

HY-W096127

Biotin-sar-oh	ADC Linker	Cancer
Biotin-sar-oh is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-169353

Mal-Exo-EEVC	ADC Linker	Cancer
Mal-Exo-EEVC is a cleavable ADC linker used in the synthesis of antibody-drug conjugate (ADC) .

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library

113 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 113 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Type

HY-126851

Fluorescein-DBCO	Dyes
Fluorescein-DBCO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Fluorescein-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-123687

DBCO-Sulfo-NHS ester sodium	Dyes
DBCO-Sulfo-NHS ester sodium is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Sulfo-NHS ester (sodium) is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-78921AG

Fmoc-3VVD-OH (GMP)	Fluorescent Dye
Fmoc-3VVD-OH (GMP) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78932G

Dap-NE hydrochloride (GMP)	Fluorescent Dye
Dap-NE hydrochloride (GMP) is Dap-NE hydrochloride (HY-78932A) produced by using GMP guidelines. Dap-NE hydrochloride is an intermediate used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131833G

Fmoc-Gly-Gly-Phe-OH (GMP)	Fluorescent Dye
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-20336G

Mc-Val-Cit-PABC-PNP (GMP)	Fluorescent Dye
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133540G

Maleimide-DOTA (GMP) Maleimido-mono-amide-DOTA (GMP)	Fluorescent Dye
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78931G

Boc-Dap-NE (GMP)	Fluorescent Dye
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-W000423G

DBCO-amine (GMP)	Fluorescent Dye
DBCO-amine GMP is a GMP grade DBCO-amine (HY-W000423). DBCO-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-amine is a click chemistry reagent, itcontains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-15578G

McMMAF (GMP) Maleimidocaproyl monomethylauristatin F (GMP)	Fluorescent Dye
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for **antibody-drug conjugates (ADC)**. McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

HY-15579BG

MMAF sodium (GMP) Monomethylauristatin F sodium (GMP)	Fluorescent Dye
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15579G

MMAF (GMP) Monomethylauristatin F (GMP)	Fluorescent Dye
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-131990G

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP)	Fluorescent Dye
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-131990). MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Type

HY-78921AG

Fmoc-3VVD-OH (GMP)	Biochemical Assay Reagents
Fmoc-3VVD-OH (GMP) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-135928

Biotin-C2-S-S-pyridine	Biochemical Assay Reagents
Biotin-C2-S-S-pyridine is a cleavable ADC linker. Biotin-C2-S-S-pyridine can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78932G

Dap-NE hydrochloride (GMP)	Biochemical Assay Reagents
Dap-NE hydrochloride (GMP) is Dap-NE hydrochloride (HY-78932A) produced by using GMP guidelines. Dap-NE hydrochloride is an intermediate used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131833G

Fmoc-Gly-Gly-Phe-OH (GMP)	Biochemical Assay Reagents
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-20336G

Mc-Val-Cit-PABC-PNP (GMP)	Biochemical Assay Reagents
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133540G

Maleimide-DOTA (GMP) Maleimido-mono-amide-DOTA (GMP)	Biochemical Assay Reagents
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78931G

Boc-Dap-NE (GMP)	Biochemical Assay Reagents
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-W000423G

DBCO-amine (GMP)	Biochemical Assay Reagents
DBCO-amine GMP is a GMP grade DBCO-amine (HY-W000423). DBCO-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-amine is a click chemistry reagent, itcontains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-15578G

McMMAF (GMP) Maleimidocaproyl monomethylauristatin F (GMP)	Biochemical Assay Reagents
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for **antibody-drug conjugates (ADC)**. McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

HY-163789

Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide	Biochemical Assay Reagents
Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

HY-15579BG

MMAF sodium (GMP) Monomethylauristatin F sodium (GMP)	Biochemical Assay Reagents
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15579G

MMAF (GMP) Monomethylauristatin F (GMP)	Biochemical Assay Reagents
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-131990G

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP)	Biochemical Assay Reagents
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-131990). MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Target	Research Area

HY-136432

Mc-Gly-Gly-Phe-Gly-PAB-OH Mc-GGFG-PAB-OH	ADC Linker	Cancer
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-136432A

Mc-Gly-Gly-Phe-Gly-PAB-OH TFA Mc-GGFG-PAB-OH TFA	ADC Linker	Cancer
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) TFA is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-P1449

Boc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate *(ADC)*.

HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate *(ADC)*.

HY-W729138

Fmoc-D-homoArg(Et)2-OH hydrochloride	ADC Linker	Others
Fmoc-D-homoArg(Et)2-OH (hydrochloride) is a Fmoc-protected derivative of D-Homoarginine (HArg) that renders peptides and proteins resistant to proteolysis by trypsin. Fmoc-D-homoArg(Et)2-OH (hydrochloride) can be used as a cleavable ADC linker to synthesize antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Target	Research Area

HY-141607

Indatuximab ravtansine BT-062; nBT062-DM4	Antibody-Drug Conjugates (ADCs) Bacterial	Cancer
Indatuximab ravtansine (BT-062) is an **antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)**) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .

HY-P99453

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P99454

Azintuxizumab vedotin ABBV-838	Antibody-Drug Conjugates (ADCs)	Cancer
Azintuxizumab vedotin (ABBV-838) is an **antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1**, a cell-surface glycoprotein expressed on multiple myeloma cells .

HY-P99854

Disitamab RC48-0	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)) .

HY-P99970

Lifastuzumab	ADC Antibody	Others
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity .

HY-P99285

Denintuzumab 1 Publications Verification hBU 12	ADC Antibody CD19	Others
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .

HY-P99043

Rovalpituzumab	Notch	Cancer
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-P99334

Vorsetuzumab mafodotin Anti-Human CD70 Recombinant antibody; SGN-75	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 **antibody-drug conjugate (ADC)*. Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC* cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .

HY-P99881

Rolinsatamab talirine ABBV 176	Drug-Linker Conjugates for ADC	Cancer
Rolinsatamab talirine (ABBV 176) is an **antibody-drug conjugate (ADC) targeting prolactin receptor (PRLR)**. Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide linker, and SGD-1882 (HY-101127) .

HY-P99967

Cantuzumab	ADC Antibody	Cancer
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .

HY-145627

Ozuriftamab vedotin BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Ozuriftamab vedotin (BA3021), an **antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2)** humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .

HY-P991041

Anti-SEZ6 Antibody (SC17)	ADC Antibody	Cancer
Anti-SEZ6 Antibody (SC17) is an anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011 .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted **antibody-drug conjugate (ADC)**. ADCT-601 has anti-tumor activity .

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent **antibody-drug conjugate** (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-P99685

Laprituximab emtansine IMGN-289; J2898A-SMCC-DM1	EGFR Antibody-Drug Conjugates (ADCs)	Cancer
Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR **antibody-drug conjugate (ADC)** consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research .

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant antibody	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

HY-P99101

Vobramitamab AEX-4089	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-P99656

Iladatuzumab MCDS0593A	ADC Antibody	Cancer
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

HY-P99813

Patritumab deruxtecan HER3-DXd; U3-1402	Antibody-Drug Conjugates (ADCs)	Cancer
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .

HY-P99349

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

HY-P990027

Izeltabart	ADC Antibody	Cancer
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .

HY-P99719

Lupartumab Amadotin BAY 1129980; Anti-C4.4a antibody-drug conjugates	Antibody-Drug Conjugates (ADCs)	Cancer
Lupartumab Amadotin (BAY 1129980) is an antibody–drug conjugate (ADC) consisting of a fully human C4.4A (LYPD3)-targeting mAb (BAY 1135626) (HY-147281) conjugated to a novel, highly potent derivative of the microtubule-disrupting cytotoxic drug auristatin via a noncleavable alkyl hydrazide linker. Lupartumab Amadotin can be used for the research of non-small cell lung cancer .

HY-P99230

Pinatuzumab	Integrin CD22	Cancer
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99612

Farletuzumab ecteribulin MORAb-202	Antibody-Drug Conjugates (ADCs)	Cancer
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

HY-P99662

Indusatumab vedotin MLN0264; TAK-264	Antibody-Drug Conjugates (ADCs) Guanylate Cyclase Apoptosis	Cancer
Indusatumab vedotin (MLN-0264; AKT-264) is an **antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis** .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first **antibody-drug conjugate (ADC) to target FGFR2** and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-P99705

Lifastuzumab vedotin RG-7599; DNIB-0600A; NaPi2b-ADC	Antibody-Drug Conjugates (ADCs)	Cancer
Lifastuzumab vedotin (RG-7599; DNIB0600A) is an **antibody-drug conjugate (ADC)** that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research .

HY-P99045

Sacituzumab	ADC Antibody TROP2	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-P99016

Enfortumab	ADC Antibody Nectin-4	Cancer
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .

HY-P9959

Inotuzumab ozogamicin CMC-544; PF-5208773; WAY-207294	Antibody-Drug Conjugates (ADCs) CD22 DNA/RNA Synthesis Apoptosis	Cancer
Inotuzumab ozogamicin (CMC-544) is an anti-CD22 **antibody-drug conjugate (ADC). Inotuzumab ozogamicin consists of a humanized IgG4 anti-CD22 mAb, covalently linked to Calicheamicin (HY-19609) via an acid-labile AcBut (HY-132261) linker. Inotuzumab ozogamicin binds to the minor groove of DNA, inducing double-strand cleavage and subsequent apoptosis**. Inotuzumab ozogamicin can be used for the study of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) .

HY-P99682

Ladiratuzumab hLIV22	ADC Antibody	Cancer
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an **antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect**. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .

HY-P99971

Gemtuzumab	ADC Antibody Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99740

Mirzotamab	CD276/B7-H3 ADC Antibody	Cancer
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .

HY-P99843

Datopotamab	TROP2 ADC Antibody	Cancer
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-P99683

Ladiratuzumab vedotin SGN-LIV1A	Antibody-Drug Conjugates (ADCs)	Cancer
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting **antibody drug conjugate (ADC)** (IC₅₀: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W034595

Eicosanedioic acid	Microorganisms Source classification	ADC Linker PROTAC Linkers
Eicosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Eicosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis

HY-117371

Hemiasterlin (-)-Hemiasterlin; Milnamide B	Alkaloids Structural Classification Classification of Application Fields Animals Marine natural products Sponge Disease Research Fields Indole Alkaloids Cancer	ADC Cytotoxin
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effcts. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-W034918

Docosanedioic acid	Structural Classification other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Plants Disease Research Fields Cancer	ADC Linker PROTAC Linkers
Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.

HY-W007324

Maleimide	Alkaloids Microorganisms Pyrrole Alkaloids Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	ADC Linker Biochemical Assay Reagents
Maleimide can be used for production of antibody-drug conjugate (ADC) which is used in cancer research. Maleimide also be leveraged for the preparation of fluorogenic probe, which is mainly used for the specific detection of thiol analytes .

Cat. No.	Product Name	Chemical Structure

HY-15583S

Auristatin F-d8
Auristatin F-d₈ is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .

HY-145397S

(4-NH2)-Exatecan-d5
(4-NH2)-Exatecan-d5 is a deuterated labeled (4-NH2)-Exatecan . (4-NH2)-Exatecan (compound A), a topoisomerase inhibitor, is a derivative of Exatecan. (4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-161022S1

FL118-C3-O-C-amide-C-NH2-d5 formate
FL118-C3-O-C-amide-C-NH2-d5 formate is a deuterium labeled FL118-C3-O-C-amide-C-NH2 formate. FL118-C3-O-C-amide-C-NH2 formate is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-114816S

N-butyryl-L-Homoserine lactone-d5

N-butyryl-L-Homoserine lactone-d₅ is the deuterium labeled N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm[1]. N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa[2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks